- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Publication
Article
Dermatology Times
Examining the Halfway Mark of 2025 in Dermatology
Author(s):
Key Takeaways
- Prademagene zamikeracel and dupilumab have been approved for epidermolysis bullosa and chronic spontaneous urticaria, respectively.
- Tinted sunscreens' efficacy in blocking high-energy visible light is crucial for preventing pigmentation issues in patients with skin of color.
Discover the latest advancements in dermatology in our June issue, including FDA approvals, innovative treatments, and expert insights shaping patient care today.
Image Credit: © Evgeniy Kalinovskiy - stock.adobe.com
Every year, the field of dermatology is filled with FDA approvals, novel research, and innovative meetings. Although FDA approvals have had a slower start this year, there has been no shortage of new research. This year’s approvals have brought prademagene zamikeracel for epidermolysis bullosa and dupilumab for chronic spontaneous urticaria, to name a couple.
As we pass the halfway mark of the year, Dermatology Times celebrates all research that shapes patient care. This month’s issue features a collection of features on treating skin conditions in patients with skin of color, artificial intelligence advancements to assist clinicians, and more.
This month’s cover feature explores the importance of visible light photoprotection, particularly focusing on the varying efficacy of tinted sunscreens in blocking high-energy visible light. Hawasatu Dumbuya, PhD, discusses how this contributes to skin darkening and pigmentation issues in patients with skin of color.
Other expert features in this month’s issue include medical students’ efforts to provide free tattoo removal for formerly incarcerated individuals, and a look at ritlecitinib plus NB-UVB for nonsegmental vitiligo with Emma Guttman-Yassky, MD, PhD.
Conference season in dermatology is also heating up with summer conferences fast approaching. Look for Dermatology Times at the 2025 Revolutionizing Atopic Dermatitis Annual Meeting, Fall Clinical Dermatology Conference for PAs and NPs, Society for Dermatology Physician Associates Summer Conference, Dermatology Education Foundation NP PA Conference, and Society for
Pediatric Dermatology Annual Meeting. Email
DTEditor@mmhgroup.com to connect on-site.
As always, Dermatology Times delivers the most up-to-date clinical content, from innovative studies and FDA approvals to exclusive interviews and expert perspectives. Stay informed with the latest data—subscribe to Dermatology Times’ e-newsletters; follow us on Facebook, LinkedIn, and X.
Mike Hennessy Jr
Mike Hennessy Jr
Chairman and CEO
MJH Life Sciences
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
